Jubilant Therapeutics, a clinical-stage biopharmaceutical company advancing precision therapeutics for myeloproliferative neoplasms (MPNs), announced that clinical results from its Phase 1/2 study of JBI-802 have been selected for an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition.

Preliminary Clinical Data

The abstract data from this ongoing Phase 1/2 study show encouraging early evidence of rapid platelet reductions and hematologic control in patients with essential thrombocythemia (ET) and related MPNs. Key findings include all 8 patients who initiated treatment at the 15 mg achieving a >50% platelet reduction or platelet normalization by Week 3, with a median time to response of 15 days.

Upcoming Event

Jubilant will host an event on December 14, 2026, following the oral presentation by Dr. Andrew McQuillan, MBBS, FRACP, FRCPA, to review the Phase 1 data presented at ASH and discuss their clinical implications. The event will be livestreamed, and a replay will be available on the Company’s website.

For more information, visit www.jubilanttx.com.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Jubilant Pharmova Limited

Jubilant Pharmova Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Jubilant moves sideways over three months, with neither buyers nor sellers taking control. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock holds at 48% of its 52-week range with RSI at 49. In other words, neither side has a clear edge right now. Revenue grows at 9.8% CAGR and the PEG stands at 99.00. The growth does not match the price the market asks. Furthermore, flat price action adds no technical catalyst. A lower price or faster revenue growth would improve the odds. Check Fundamentals of Jubilant Pharmova Limited.

Morepen Laboratories Limited (MOREPENLAB) announced the launch of its first prescription (Rx) generic product, Desloratadine Tablets USP, 5 mg, in 100-count and 500-count packs for distribution in the U.S. market. This initiative is being undertaken through its wholly owned U.S. arm, Morepen Bio Inc. Building on its established API position, this move extends the company’s participation further along the pharmaceutical value chain into finished-dosage medicines and U.S. distribution.

Strategic Expansion into Prescription Market

Sanjay Suri, Managing Director of Morepen Laboratories Limited, said, “Our long-standing API relationships in regulated markets provide a strong foundation for Morepen’s next phase of growth. Alongside our expanding CDMO business, we are selectively extending our capabilities into finished-dosage development and U.S. distribution. This reflects our strategy to build a more integrated, R&D-led pharmaceutical business with sustainable, long-term growth opportunities.”

Regulatory Milestones

The prescription generics expansion follows Morepen’s earlier U.S. OTC product introductions. Separately, the company has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Phosphate Tablets USP, 25 mg, 50 mg, and 100 mg. This milestone demonstrates Morepen’s growing capabilities in formulation development, analytical science, and regulatory filings. The application is currently under regulatory review.

Looking ahead, Morepen intends to pursue additional U.S. prescription generic filings and distribution opportunities where its established API and pharmaceutical R&D capabilities provide a competitive advantage. The company may also evaluate selected opportunities in high-potency APIs (HPAPIs) and oncology, subject to development feasibility, regulatory requirements, and market conditions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Morepen Laboratories Limited

Morepen Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Morepen gains 110.3% over three months and trades near its 52-week highs. Thin margins at 7.2% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The PEG of 1.39 sits close to fair value. The stock is neither a clear buy nor obviously expensive. Buyers show up with 1.7x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 110.3% in three months on 8.4% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Morepen Laboratories Limited.

Cohance Lifesciences Limited (COHANCE) showcased a clear sequential recovery in its Q2 FY27 investor presentation, with revenue up 13% QoQ and adjusted EBITDA margin improving to 10% from 2% in Q1. The integrated capabilities of One Cohance are strengthening the growth platform.

Strategic Progress

The integration of One Cohance is driving operational and commercial progress across businesses. In the Pharma CDMO segment, the order and reload position for Q3 and Q4 has improved materially. Cohance secured two new commercial and one late-stage programme with large global pharma customers, strengthening relationships and medium-term growth opportunities. In the nucleic acid business, Sapala’s strong performance is supported by increasing integration of its specialised chemistry and customer relationships with Cohance’s development and manufacturing network.

Financial Performance

API+ revenue grew year-on-year, supported by selective pricing actions, while lower API volumes, shipment phasing, and higher raw-material costs impacted margins. Specialty Chemicals declined YoY due to lower AgChem volumes, pricing pressure, and programme phasing, while Performance Materials remained relatively stable. The company plans to announce investments in capex towards building capabilities in adjacencies and R&D to unlock the full potential of the One Cohance platform.

Looking Ahead

H2 FY27 revenue and EBITDA are expected to grow year-on-year, supported by continued recovery and progressive integration of Cohance’s capabilities to unlock platform potential. The H2 focus is on improving revenue mix and utilisation to support progressive margin recovery.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Cohance Lifesciences Limited

Cohance Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Cohance moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 5.0% leave limited room for error — any demand softness or cost spike hits the bottom line hard. 1 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. The stock holds at 30% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. The stock rises 5.0% in three months on 18.3% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Cohance Lifesciences Limited.